Enadenotucirev is under clinical development by PsiOxus Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Enadenotucirev’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Enadenotucirev Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Enadenotucirev overview

Enadenotucirev (ColoAd1) is under development for the treatment of solid tumors including metastatic bladder cancer, salivary gland cancer, fallopian tube cancer, squamous and non-squamous non-small cell lung cancer, primary peritoneal cancer, colon cancer, urothelial cell carcinoma, head and neck cancer squamous cell carcinoma, advanced epithelial tumor. It is administered through intratumoral, intravenous and intraperitoneal routes. It is a chimeric oncolytic vaccine consists of chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions. It was also under development for metastatic colorectal cancer, breast cancer, platinum resistant ovarian cancer, renal cell carcinoma.

PsiOxus Therapeutics overview

PsiOxus Therapeutics (PsiOxus), formerly Myotec Therapeutics, is a drug company that develops novel therapeutics for cancer and other clinically unmet diseases. It provides pipeline product portfolio such as an oncolytic vaccine and a dual action anabolic catabolic transforming agent. The company also has an antibody armed oncolytic platform under development. PsiOxus’s products find application in the treatment of various cancer diseases such as cachexia, sarcopenia, metastatic cancer and solid tumours, among others. It holds expertise in enhancing the therapeutic potency, safety and delivery kinetics through genetic modification to produce cancer vaccines. PsiOxus is headquartered in Abingdon, Oxfordshire, the UK.

Quick View Enadenotucirev LOA Data

Report Segments
  • Innovator
Drug Name
  • Enadenotucirev
Administration Pathway
  • Intraperitoneal
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: PsiOxus Therapeutics
  • Originator: PsiOxus Therapeutics and Bayer
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.